Drug Profile
Interferon beta 1a - Synairgen
Alternative Names: AZD 9412; inhaled interferon beta - Synairgen; SNG-001Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Southampton
- Developer AIDS Clinical Trials Group; Synairgen
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Immunostimulants; Interferon beta-1a replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Chronic obstructive pulmonary disease
- No development reported Influenza virus infections
- Discontinued Asthma
Most Recent Events
- 21 Sep 2023 Synairgen plans clinical trials for SNG 001 in H1 2024
- 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (Inhalation) (NCT04518410)
- 19 Feb 2023 Updated efficacy and adverse events data from a phase-II ACTIV-2 trial in COVID-2019 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)